SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220235

Enrollment

Registered

2006-04-21

Start date

2006-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : Aliskiren INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : O

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria - Age: 20-80 years old - Gender: Male or female - Status: Outpatients - Elevated Serum Creatinine Exclusion criteria - Patients suspected of malignant hypertension - Patients with a clinically significant allergy - Patients who have received other investigational drug Other protocol-defined inclusion/exclusion criteria may apply

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary Outcomes: Adverse events after 8 weeks Secondary Outcomes: Change from baseline in mean sitting systolic blood pressure after 8 weeks; Change from baseline in mean sitting diastolic blood pressure after 8 weeks; Mean sitting systolic blood pressure is 20 mmHg after 8 weeks; Mean sitting diastolic blood pressure is 10 mmHg after 8 weeks; Blood pressure <140/90 after 8 weeks	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026